Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors

OBJECTIVES: Although many newer diabetes medications have become available in the last decade, most have not been widely studied in populations with chronic kidney disease under routine care. Linagliptin, a recently marketed dipeptidyl peptidase 4 (DPP‐4) inhibitor, is the only agent in the U.S. tha...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Endocrinol Diabetes Metab
Κύριοι συγγραφείς: Patorno, Elisabetta, Gopalakrishnan, Chandrasekar, Bartels, Dorothee B., Brodovicz, Kimberly G., Liu, Jun, Schneeweiss, Sebastian
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley and Sons Inc. 2017
Θέματα:
Original Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360917/
https://ncbi.nlm.nih.gov/pubmed/30815542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/edm2.5
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια